FOLLOWUS
Treatment of middle/late stage primary hepatic carcinoma by Chinese medicine comprehensive therapy: A prospective randomized controlled study
Treatment of middle/late stage primary hepatic carcinoma by Chinese medicine comprehensive therapy: A prospective randomized controlled study
- 中国结合医学杂志（英文版） 2010年16卷第2期 页码：102-108
- Affiliations：
Department of Oncology, Foshan Municipal Hospital of Traditional Chinese Medicine,Guangdong,China
- Author bio：
- Funds：Supported by Guangdong Administration of Sciences and Technology (No. 2005B36001012)
DOI：10.1007/s11655-010-0102-3
中图分类号：纸质出版日期：2010，
网络出版日期：2010-5-16，
Scan for full text
Tian, Hq., Li, Hl., Wang, B. et al. Treatment of middle/late stage primary hepatic carcinoma by Chinese medicine comprehensive therapy: A prospective randomized controlled study., Chin. J. Integr. Med. 16, 102–108 (2010). https://doi.org/10.1007/s11655-010-0102-3
Hua-qin Tian, Hong-liang Li, Bin Wang, et al. Treatment of middle/late stage primary hepatic carcinoma by Chinese medicine comprehensive therapy: A prospective randomized controlled study[J]. Chinese Journal of Integrative Medicine, 2010,16(2):102-108.
Tian, Hq., Li, Hl., Wang, B. et al. Treatment of middle/late stage primary hepatic carcinoma by Chinese medicine comprehensive therapy: A prospective randomized controlled study., Chin. J. Integr. Med. 16, 102–108 (2010). https://doi.org/10.1007/s11655-010-0102-3 DOI：
Hua-qin Tian, Hong-liang Li, Bin Wang, et al. Treatment of middle/late stage primary hepatic carcinoma by Chinese medicine comprehensive therapy: A prospective randomized controlled study[J]. Chinese Journal of Integrative Medicine, 2010,16(2):102-108. DOI： 10.1007/s11655-010-0102-3.
摘要
To observe the efficacy of Chinese medicine comprehensive therapeutic project in treating the middle/late stage primary hepatic carcinoma (PHC). With prospective randomized controlled design
97 patients with PHC were assigned to the test group (49 cases) treated with Chinese medicine comprehensive therapy using Oleum fructus bruceas intervention combining oral intake of Ganji Decoction (肝积方) and external application of Ailitong (癌理通)
and the control group (48 cases) treated with chemotherapeutic agents combining iodized oil chemo-embolization and analgesics. The immediate and long-term efficacy
adverse reaction
pain-relieving initial time (PRIT) and pain-relieving sustained time (PRST) of the treatment
as well as the change in relieving patients’ quality of life (QOL) were observed. The difference between the two groups in illness control rate was statistically insignificant (P>0.05)
but the adverse reaction occurence rate in the test group was lesser than that in the control group (P<0.05). PRIT was insignificantly different in the two groups (P>0.05)
but the PRST was significantly superior in the test group than that in the control group (10.37±2.18 h vs 7.78±1.95 h
P<0.01). After treatment
the increased Karnofsky scores in the test group indicated that the patients’ somatic activity
symptoms and QOL were improved significantly
which were significantly superior to those in the control group (P<0.05). The survival rate in the two groups was similar at the 3rd month after treatment
but the test group did show superiority in terms of half- and 1-year survival rate (65.9% vs 42.5% and 38.6% vs 18.1%
respectively
P<0.05). The median survival time in the test group was 8.9 months and that in the control group was 5.3 months. Chinese medicine comprehensive therapy is an effective treatment for the middle/late stage patients of PHC
and it could extend the PRST
improve the patients’ QOL and long-term survival with less adverse reaction.
Abstract
To observe the efficacy of Chinese medicine comprehensive therapeutic project in treating the middle/late stage primary hepatic carcinoma (PHC). With prospective randomized controlled design
97 patients with PHC were assigned to the test group (49 cases) treated with Chinese medicine comprehensive therapy using Oleum fructus bruceas intervention combining oral intake of Ganji Decoction (肝积方) and external application of Ailitong (癌理通)
and the control group (48 cases) treated with chemotherapeutic agents combining iodized oil chemo-embolization and analgesics. The immediate and long-term efficacy
adverse reaction
pain-relieving initial time (PRIT) and pain-relieving sustained time (PRST) of the treatment
as well as the change in relieving patients’ quality of life (QOL) were observed. The difference between the two groups in illness control rate was statistically insignificant (P>0.05)
but the adverse reaction occurence rate in the test group was lesser than that in the control group (P<0.05). PRIT was insignificantly different in the two groups (P>0.05)
but the PRST was significantly superior in the test group than that in the control group (10.37±2.18 h vs 7.78±1.95 h
P<0.01). After treatment
the increased Karnofsky scores in the test group indicated that the patients’ somatic activity
symptoms and QOL were improved significantly
which were significantly superior to those in the control group (P<0.05). The survival rate in the two groups was similar at the 3rd month after treatment
but the test group did show superiority in terms of half- and 1-year survival rate (65.9% vs 42.5% and 38.6% vs 18.1%
respectively
P<0.05). The median survival time in the test group was 8.9 months and that in the control group was 5.3 months. Chinese medicine comprehensive therapy is an effective treatment for the middle/late stage patients of PHC
and it could extend the PRST
improve the patients’ QOL and long-term survival with less adverse reaction.
关键词
hepatic cancerChinese medical treatmentcomprehensive therapy
Keywords
hepatic cancerChinese medical treatmentcomprehensive therapy
references
National Cancer Prevention and Control Office, Chinese Anti-cancer Association. Standardized diagnosis and treatment of common malignant tumors in China. Volume 2. Beijing: Joint Press of Beijing Medical University and Peking Union Medical College, 1990:54–55.
Sun Y, ed. Medical oncology. Beijing: People’s Medical Publishing House, 2001:995–996.
Wang CH, Fang JQ, Zhang CZ, Lin Y, Luo YM. Establishment and evaluation of measuring scale of QOL on hepatoma. Chin J Behav Med (Chin) 1998;37:170–173.
Ko KH, Jo M, Lee JH. Antiinflammatory and analgesic activities, and slin irritation test of piroxicam patch. J Appl Pharmacol 1994;2:71–76
Liu LM, Yang YF, eds. Grababin medicinarum particularum of oncology. Beijing: People’s Medical Publishing House, 2003:651–652.
Jiang WQ, Sun XF, Zhang L, Huang HQ. Practical manual of prescription on oncology. Guangzhou: Guangdong Science and Technology Press, 2003:524–528.
Yamada R, Sato M, Kawabata M. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983;148:397.
Chen XM, Luo PF, Hu JL, Shao PJ, Zhou ZJ. Delayed adverse reactions of liver after transcatheter hepatic arterial chemoembolization with anticancer drugs mixed lipiodol. Cancer (Chin) 1994;13:50–52.
Gao QY. Prospective, controlled study of chemoembolization expectant treatment on hepatoma. Foreign Med Sci (Oncol Sec, Chin) 1995;22:313.
Wang F, Cao Y, Liu HY, Fu ZD, Han R. Study of Brucea javanica oil emulsion induced HL-60 cell apoptosis. Chin J Tradit Chin Med (Chin) 2003;28:759–762.
Wang H, Zhang B, Wu GJ, Zhang G, Xin JG. Brucea mouse anticancer at the role of bladder cancer. J Fourth Milit Med Univ (Chin) 2001;22:1886.
Lin HY, Wu JM, Zhang WS. Study progress of oleum fructus bruceae. Chin J Exp Pharmacol Tradit Chin Med Form (Chin) 2006;12:65–69.
Li WJ, Deng L, Ai LX, Li JP. Oleum of brucea javanicalipidol used in hepatic arterial embolization to treat hepatocellular carcinoma: an effect analysis. Imag Diagn intervent radiol (Chin) 2005;14:30–31.
Ma L, Zhang YN. Effects of seminal oil emulsion of Brucea javanica on apoptosis and apoptosis-related genes in human hepatocellular carcinoma cells. World Chin J Digestol (Chin) 2004;12:559–562.
Wu WY. The application of Chinese medicine in interventional transcatheter arterial treatment of liver cancer. Chin J Integr Tradit West Med Liver Dis (Chin) 1998;8:188–191.
Shen YJ, Chen CX, eds. Pharmacology of traditional Chinese medicine. Shanghai: Shanghai Science and Technology Press; 2008: 58–61, 125–127, 320–324.
Huang XQ, Tian HQ, Liang GW. Affection of the drug of Ganjifang containing serum to the hepG2 cell proliferation. Chin J Pract Med (Chin) 2006;19:2613–2615.
Chen XZ, Tian HQ, Huang XQ, Liang GW, Huang ZQ. Effect of Ganjifang to blood stasis of patients with advanced PLC. Shaanxi Tradit Chin Med (Chin) 2005;26:891–893.
Tian HQ, Xu XQ, Liang GW, Huang ZQ, Deng JM. Effect of Ganjifang to SIL-2R and T cells of patients with advanced PLC. Chin J Mod Med (Chin) 2001;11(10):89–90.
Tian HQ, Liang GW, Huang XQ, Huang ZQ. Effect of Ganjifang combined with Argon-helium cryoablation and TACE treating 48 patients with advanced PLC. New J Tradit Chin Med (Chin) 2005;37:21–22.
Tian HQ, Liang GW, Tao Y, Huang ZQ, Yu SY, Ye WY. Interventional treatment of liver cancer with traditional Chinese medicine clinical research. Henan J Tradit Chin Med (Chin) 2001;16:47–48.
Liu JX, Xu DF, Fang ZZ. Effect of Chansu Ointment for cancer pain. J Tradit Chin Med (Chin) 1993;34:281–282.
0
浏览量
379
Downloads
16
CSCD
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 邮编：100091
- 联系电话：010-62886827, 62877592 传真：010-62874291
- 技术支持由北京北大方正电子有限公司提供 京ICP备05067934号-1
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
